CF-2-17

CF-2-17: sourced facts only. name: "The optimized compound, CF-2-17, demonstrated potent dual inhibition of FLT3 (IC50 = 1.1 nmol/L) and HDACs (IC50 = 9.6 nmol/L), and exhibited a 27-fold selectivity for HDAC1 over HDAC6." [PMID:42592389]; target: "The optimized compound, CF-2-17, demonstrated potent dual inhibition of FLT3 (IC50 = 1.1 nmol/L) and HDACs (IC50 = 9.6 nmol/L), and exhibited a 27-fold selectivity for HDAC1 over HDAC6." [PMID:42592389]; developer: "Department of Medicinal Chemistry, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, Shandong Basic Science Special Academic Zone (Pharmacy), School of Pharmaceutical Sciences, Cheelo College of Medicine, Shandong University, Jinan 250012, China." [PMID:42592389]; stage: "In the MOLM-13 (FLT3-ITD) xenograft model, oral administration of CF-2-17 showed antitumor efficacy comparable to combination therapy, without observable toxicity." [PMID:42592389]